White House launches TrumpRx; Sanofi joins drugmakers offering steep prescription discounts

White House unveils TrumpRx with Sanofi among signatories

Sanofi is among a group of drugmakers that the White House says commit to steep discounts under the administration’s new TrumpRx program, which the White House is formally unveiling Thursday evening. The initiative is presented as a means to let Americans buy prescription medicines at lower cost by enabling some manufacturers to sell directly to consumers through the program. Officials name conditions targeted for savings as diabetes, asthma, HIV, hepatitis C, multiple sclerosis and cardiovascular disease.

Sanofi’s participation signals a broader industry willingness to experiment with alternative distribution and pricing arrangements outside traditional pharmacy benefit structures. By joining agreements that the White House says include Amgen, Merck, Novartis and Bristol Myers Squibb, Sanofi potentially faces both new commercial pathways and scrutiny over how discounts are administered and which medicines are offered. The move places manufacturers closer to patients at the point of sale, raising questions about logistics, supply chain adjustments and the use of company discounts in lieu of insurer-negotiated rebates.

For Sanofi and its peers, TrumpRx tests whether one-off discount deals can expand access while preserving relationships with wholesalers, pharmacy benefit managers and retail chains. The administration frames the program as saving Americans billions and expanding access, but the long-term effects on formularies, prescribing patterns and manufacturer margins remain uncertain. If sustained, the model could prompt other companies in the industry to weigh direct-to-consumer pricing experiments alongside existing market channels.

Details and logistics remain unclear

Officials and media reports differ on the exact scope: the White House previously names nine major companies, while CNN reports at least 16 manufacturers have negotiated to participate. Specifics such as which pharmacies will carry TrumpRx medications, patient eligibility rules and the precise formularies are still largely unsettled, leaving hospitals, retail chains and insurers awaiting implementation guidance.

Reactions from industry and advocates are mixed

Industry figures like GoodRx CEO Wendy Barnes voice support, saying the initiative aligns with efforts to lower prices, while analysts and consumer advocates warn that the program’s mechanics and long-term impacts on competition, access and existing payer arrangements are not yet resolved. The launch follows other Trump health initiatives, and the event features CMS Administrator Dr. Mehmet Oz and design director Joe Gebbia as part of the administration’s push to highlight negotiated price examples such as substantially reduced prices for specific drugs from Bristol Myers Squibb and Merck.